Hugel Inc
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults… Read more
Hugel Inc (145020) - Total Liabilities
Latest total liabilities as of September 2025: ₩96.88 Billion KRW
Based on the latest financial reports, Hugel Inc (145020) has total liabilities worth ₩96.88 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hugel Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Hugel Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hugel Inc Competitors by Total Liabilities
The table below lists competitors of Hugel Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Telling Telecommunication Holding Co Ltd
SHE:000829
|
China | CN¥21.96 Billion |
|
BELL FOOD GRP AG NA.SF0,5
F:BWGA
|
Germany | €1.57 Billion |
|
Jiangnan Mould & Plastic Technology Co Ltd
SHE:000700
|
China | CN¥3.39 Billion |
|
Vapores
SN:VAPORES
|
Chile | CL$62.81 Million |
|
Amara Raja Batteries Limited
NSE:ARE&M
|
India | ₹31.10 Billion |
|
Yantai Tayho Advanced Materials Co Ltd
SHE:002254
|
China | CN¥7.38 Billion |
|
Shanghai Fortune Techgroup Co Ltd
SHE:300493
|
China | CN¥821.15 Million |
|
Lindab International AB
ST:LIAB
|
Sweden | Skr7.31 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Hugel Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hugel Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hugel Inc (2014–2024)
The table below shows the annual total liabilities of Hugel Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩98.63 Billion | -34.06% |
| 2023-12-31 | ₩149.57 Billion | -41.95% |
| 2022-12-31 | ₩257.67 Billion | +10.75% |
| 2021-12-31 | ₩232.65 Billion | +10.96% |
| 2020-12-31 | ₩209.67 Billion | +7.42% |
| 2019-12-31 | ₩195.19 Billion | +2.44% |
| 2018-12-31 | ₩190.55 Billion | +52.17% |
| 2017-12-31 | ₩125.22 Billion | +201.71% |
| 2016-12-31 | ₩41.50 Billion | +61.33% |
| 2015-12-31 | ₩25.73 Billion | -41.58% |
| 2014-12-31 | ₩44.04 Billion | -- |